🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Vilanterol (VI) (25 mcg)

Found 49 matching trials

Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)

PHASE2

Batefenterol is a novel bifunctional molecule that combines muscarinic anta...

Status

Completed

Location

GSK Investigational Site

Start Date

2015-11-06

Trial ID

NCT02570165

Treatments Being Tested

Batefenterol Umeclidinium/ Vilanterol Placebo

The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium

PHASE3

The primary objective is to compare the efficacy of UMEC/VI Inhalation Powd...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-09-15

Trial ID

NCT01899742

Treatments Being Tested

Umeclidinium/Vilanterol 62.5/25 mcg Tiotropium 18 mcg

Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses

PHASE1

This study will evaluate the pharmacokinetics of FF, UMEC and VI administer...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-07-15

Trial ID

NCT01894386

Treatments Being Tested

FF 400 mcg UMEC 500 mcg UMEC 250 mcg VI 100 mcg

A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

This study is a 12-week, multicenter, randomized, double blind, parallel gr...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-09-01

Trial ID

NCT02152605

Treatments Being Tested

UMEC/VI Placebo

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

PHASE3

A once-daily 'closed' triple FDC therapy of FF/UMEC/VI via a single ELLIPTA...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-10-13

Trial ID

NCT02924688

Treatments Being Tested

FF/UMEC/VI (100/31.25/25) mcg FF/UMEC/VI (100/62.5/25) mcg FF/UMEC/VI (200/31.25/25) mcg FF/UMEC/VI (200/62.5/25) mcg FF/VI (100/25) mcg FF/VI (200/25) mcg Fluticasone/salmeterol (FSC)Albuterol/salbutamol ELLIPTA DPI DISKUS DPI METERED-DOSE INHALER (MDI)

A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

PHASE4

This is a multicenter, randomized, double-blind, placebo-controlled, 2-peri...

Status

Completed

Location

GSK Investigational Site

Start Date

2015-01-23

Trial ID

NCT02275052

Treatments Being Tested

UMEC/VI DPI Placebo DPI Albuterol/salbutamol MDI

Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

PHASE4

This is a multi-center, randomized, double-blind, parallel-group study. The...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-01-28

Trial ID

NCT01957150

Treatments Being Tested

Fluticasone Furoate/Vilanterol Vilanterol

An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients

PHASE4

The primary objective of this study is to assess the effect of umeclidinium...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-07-14

Trial ID

NCT02799784

Treatments Being Tested

UMEC/VI TIO/OLO Albuterol/salbutamol

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.

PHASE3

This is a Phase III, multicenter, randomized, double-blind, stratified, par...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-09-20

Trial ID

NCT01686633

Treatments Being Tested

Fluticasone Furoate/ Vilanterol 200/25 mcg Fluticasone Furoate/ Vilanterol 100/25 mcg Fluticasone Furoate 100 mcg

Relovair PD PK in Chinese Healthy Subjects

PHASE1

In this study, fluticasone furoate (FF) and vilanterol (VI) in different do...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-12-05

Trial ID

NCT01711463

Treatments Being Tested

Fluticasone Furoate/Vilanterol Placebo

Previous Next